Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation

 
• By Anju Ghangurde

Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.

Holding_Arrow
Glenmark Plans To Sew Up String Of Alliances Over Near Term • Source: Shutterstock

More from Business

More from Scrip